Shamburg News · 8-K filed Nov 13, 2026, 8:05 AM EST

Fortress Biotech Reports Third Quarter 2026 Net Revenue of $19.2 Million and Net Loss Per Share of $0.23

FBIO · Fortress Biotech, Inc.

  • Earnings
  • Materiality: high

Fortress Biotech furnished a press release reporting third quarter 2026 results for the quarter ended September 30, 2026. Consolidated net revenue was $19.2 million, compared with $17.6 million a year earlier, and net loss attributable to common stockholders was $(7.9) million, or $(0.23) per share basic and diluted. The company also reported that it repaid its $15.0 million remaining Oaktree credit facility principal in full in September 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001104659-26-126525.

Written from the filing by Shamburg Markets. Figures are as reported by the company.